Butterfly Network, Inc.

Executive Summary

SELL, Medium conviction. Rated SELL, Medium conviction. BFLY's Q3 results were strong, with 52% revenue growth, a 73% adjusted gross margin, and a raised FY26 outlook, but the shares still price the company at 16.24x TTM sales while adjusted EBITDA remains negative. The 37.4% retreat from the 52-week high reduces near-term downside, yet does not bridge the gap between a $2.0B market capitalization and a business guiding to $123M-$126M of FY26 revenue.

Investment Thesis

The market is assigning BFLY a mature-platform valuation before the platform has mature economics. The company has made tangible progress: Embedded expanded quickly, gross margin reached 73% in Q3, and management improved its FY26 loss outlook. Those are not cosmetic changes. They show that the business can sell higher-margin products and that the cost structure has become more scalable.

The problem is the price paid for that progress. At $6.39, BFLY is valued at $2.0B despite a FY26 revenue guide of only $123M-$126M and an expected adjusted EBITDA loss of $12M-$15M. That valuation assumes not merely that Embedded will grow, but that it will become repeatable, durable, and sufficiently software-like to support a premium far beyond the medical-device peer set. Q3 Embedded revenue of $11.1M validates demand, but management explicitly warns that revenue is tied to partner milestones and contract timing. A lumpy revenue source deserves a discount until renewals, expansion revenue, and customer concentration are disclosed.

The core POCUS business also matters because it is the stabilizer beneath the AI narrative. Its 5% Q3 growth is positive but modest, while international revenue declined 5% YoY. Enterprise bookings, federal authorization, and Home & Community Care provide credible growth vectors, yet none is currently large enough to remove reliance on Embedded. The P5.1 device launch is a meaningful 2027 opportunity, but it also adds execution and adoption risk before the company reaches its stated 2028 EBITDA and cash-flow-positive objective.

The stock has already fallen 37.4% from its 52-week high, so this is not a simple momentum short. Elevated short interest and a positive options gamma regime can create sharp rallies if Q4 Embedded conversion beats expectations. Still, the 5.7% premium to the 200-day average after a 28.68% one-month decline does not establish a washed-out valuation. The case depends on premium growth continuing for several quarters without a capital raise through the ATM. Until that evidence emerges, the appropriate action is to avoid paying today for 2028 profitability.

Key Metrics

Financial Strength

The balance sheet is adequate for the current operating plan, with low leverage and strong current liquidity, but it does not yet fund a shareholder-return story because free cash flow remains negative on the reported LTM basis. Margin direction is clearly better, driven by Embedded mix, cost discipline, and a tariff refund, yet the difference between a 73% adjusted gross margin and a -49.2% LTM operating margin remains substantial. The $150M ATM is therefore financially prudent but economically costly if used at a depressed share price.

Competitive Position

Butterfly's moat is its integrated handheld-ultrasound hardware, installed clinical workflow, enterprise relationships, and data-bearing deployment model, not a dominant standalone imaging monopoly. FedRAMP authorization adds a meaningful access advantage in federal procurement, while P5.1 could strengthen image quality in early 2027. Durability remains limited until Embedded partnerships prove recurring and the company shows that AI improves Butterfly's economics rather than making image interpretation a feature supplied by larger platforms.

Management & Guidance

Management's current outlook is materially better than its prior plan: CFO John Doherty said, "We expect revenue to be between $123 million and $126 million, an improvement of $4 million at the bottom and $3 million at the top of the range from our previous guidance." The Q3 beat and four 2026 EPS beats support confidence in the near-term revenue and loss range. Confidence should remain measured because Q4 Embedded timing is explicitly lumpy, international demand was down, and management's 2028 adjusted EBITDA and cash-flow-positive goal is still two years away.

Segment Analysis

• Embedded ($11.1M Q3 2026 revenue): Revenue grew more than 1,000% YoY, led by Midjourney and BCI partnerships; management flags milestone-based contract timing as lumpy.
• Core POCUS (Not separately disclosed): Revenue increased 5% YoY in Q3, supported by enterprise wins, U.S. probe-unit growth, and HHS demand.
• International (Not separately disclosed): Revenue fell 5% YoY in Q3 as distributor inventory and delayed deal closures weighed on results.
• U.S. federal and Home & Community Care (Not separately disclosed): FedRAMP authorization broadens federal access; Home & Community Care began scanning in November with initial revenue expected in Q4.

Capital Allocation

Capital allocation is defensive rather than shareholder-return oriented: reported LTM free cash flow through 2026-06-30 was -$0.0B, with $0.0B of capex, buybacks, and dividends disclosed. The company carries no meaningful total debt and an as-of-2026-09-30 current ratio of 3.58, but has also filed a $150M shelf and established a $150M ATM. That liquidity optionality protects product investment, but it places dilution risk ahead of any buyback or dividend case.

Management Execution & Track Record

Management broadly delivered the FY25 growth objective set at the 2024 Q4 call: it guided to approximately 20% growth on $96M-$100M of revenue, and FY2025 revenue was reported at $0.1B with 20.5% YoY growth. The profitability repair has been more convincing than the original plan implied: the 2024 Q4 call guided to a $37M-$42M FY25 adjusted EBITDA loss, whereas the current FY26 outlook is a $12M-$15M loss and Q3 adjusted EBITDA loss was only $1.2M. Credibility improved after four consecutive 2026 EPS beats, including -$0.01 versus -$0.03532 in Q3, although the -$0.13 EPS miss versus -$0.07 in 2025 Q3 shows the record is not clean. Strategy has shifted from iQ3 pricing, Octiv, and early HomeCare pilots toward Embedded partnerships, federal access, and P5.1; the 2028 cash-flow-positive target and early-2027 chip launch remain unproven commitments.

Positioning & Flows

Ownership is concentrated, with the top three institutions holding 48.9% and insiders holding 9.8%; BlackRock, Glenview, Hood River, Vanguard, and State Street are named holders. Short interest is elevated at 33.6M shares, or 15.54% of shares, with 5.2 days to cover, creating squeeze potential around earnings but also signaling substantial skepticism. Near-dated options are in a positive gamma regime, although the provided data does not disclose usable strike values for the call wall, put wall, or zero-gamma level.

Bull Case

• Embedded revenue was $11.1M in Q3, up more than 1,000% YoY, led by Midjourney and new BCI partnerships.
• Q3 revenue of $32.6M grew 52% YoY and exceeded the high end of guidance by 9%, allowing management to raise FY26 revenue guidance by $3M-$4M.
• Five seven-figure and 10 six-figure enterprise TCV deals closed in Q3, while U.S. HHS revenue increased 15% YoY and U.S. probe units rose 9%.
• FedRAMP authorization opens a federal channel, and the P5.1 handheld chip is targeted for early 2027, potentially improving image quality and software-enabled differentiation.

Bear Case

• Embedded is milestone-driven and lumpy, and Q4 guidance of $31M-$34M still includes an adjusted EBITDA loss of $3M-$6M.
• International revenue declined 5% YoY in Q3 as distributors worked through inventory, exposing the limits of broad-based demand despite the 52% consolidated growth rate.
• FY2025 operating margin was -81.3% and LTM operating margin was -49.2%, leaving little evidence that GAAP profitability is near.
• A $150M ATM and $150M shelf create material dilution capacity relative to the $2.0B market capitalization, even though management says there is no immediate cash need.

Valuation & Price Target

Engine price target $4.42 (-30.9% vs current), Low confidence.

• P/S Multiple: $0.91 (14% weight)
• Quality-adjusted: $6.85 (20% weight)

The SELL rating aligns with the quant baseline SELL and its $4.42 sales-quality-blend target, which implies 30.9% downside from $6.39. The qualitative evidence is stronger than the engine's low-conviction label suggests, including the raised FY26 revenue guide, 73% Q3 adjusted gross margin, and sharply lower EBITDA losses, so conviction is Medium rather than Low. Those improvements do not justify overriding the valuation signal because BFLY trades at 16.24x TTM sales versus 2.6x for peers while guiding to another adjusted EBITDA loss. The lone sell-side Strong Buy is low-signal context from one firm and does not resolve that valuation mismatch.

Risk Assessment

Risk score 54/100 (Moderate). The primary risk is that Embedded revenue, already $11.1M in Q3, converts into recurring high-margin platform revenue faster than expected and makes the 16.24x TTM P/S multiple sustainable.

The Bottom Line

BFLY rates a SELL at Medium conviction for the next 6-12 months. The company is improving faster than its historical losses suggest, but the market already values it as though Embedded revenue is proven, recurring, and highly profitable. A sustained sequence of Embedded renewals, core POCUS acceleration beyond 5%, and evidence that the 2028 profitability target can be reached without ATM dilution would change the view. Until then, the $4.42 base value is a more defensible entry point than $6.39.